Literature DB >> 23265668

RadNuc: a graphical user interface to deliver dose rate patterns encountered in nuclear medicine with a 137Cs irradiator.

Jordan B Pasternack1, Roger W Howell.   

Abstract

UNLABELLED: The temporal variations in absorbed dose rates to organs and tissues in the body are very large in diagnostic and therapeutic nuclear medicine. The response of biological endpoints of relevance to radiation safety and therapeutic efficacy is generally modulated by dose rate. Therefore, it is important to understand how the complex dose rate patterns encountered in nuclear medicine impact relevant biological responses. Accordingly, a graphical user interface (GUI) was created to control a cesium-137 irradiator to deliver such dose rate patterns.
METHODS: Visual Basic 6.0 was used to create a user-friendly GUI to control the dose rate by varying the thickness of a mercury attenuator. The GUI facilitates the delivery of a number of dose rate patterns including constant, exponential increase or decrease, and multi-component exponential. Extensive visual feedback is provided by the GUI during both the planning and delivery stages.
RESULTS: The GUI controlled irradiator can achieve a maximum dose rate of 40 cGy/h and a minimum dose rate of 0.01 cGy/h. Addition of machined lead blocks can be used to further reduce the minimum dose rate to 0.0001 cGy/h. Measured dose rate patterns differed from programmed dose rate patterns in total dose by 3.2% to 8.4%.
CONCLUSION: The GUI controlled irradiator is able to accurately create dose rate patterns encountered in nuclear medicine and other related fields. This makes it an invaluable tool for studying the effects of chronic constant and variable low dose rates on biological tissues in the contexts of both radiation protection and clinical administration of internal radionuclides.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23265668      PMCID: PMC3840905          DOI: 10.1016/j.nucmedbio.2012.11.005

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  22 in total

1.  Effects of exposure to low-dose-rate (60)co gamma rays on human tumor cells in vitro.

Authors:  Catherine R Mitchell; Melvyn Folkard; Michael C Joiner
Journal:  Radiat Res       Date:  2002-09       Impact factor: 2.841

2.  Analysis of mortality among Canadian nuclear power industry workers after chronic low-dose exposure to ionizing radiation.

Authors:  Lydia B Zablotska; J Patrick Ashmore; Geoffrey R Howe
Journal:  Radiat Res       Date:  2004-06       Impact factor: 2.841

Review 3.  Radiobiology of dose-rate patterns achievable in radioimmunoglobulin therapy.

Authors:  L E Dillehay; J R Williams
Journal:  Front Radiat Ther Oncol       Date:  1990

4.  Dose-rate effects in biologically targeted radiotherapy.

Authors:  J A O'Donoghue; T E Wheldon
Journal:  Int J Radiat Biol       Date:  1989-11       Impact factor: 2.694

5.  Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Authors:  G A Wiseman; C A White; R B Sparks; W D Erwin; D A Podoloff; D Lamonica; N L Bartlett; J A Parker; W L Dunn; S M Spies; R Belanger; T E Witzig; B R Leigh
Journal:  Crit Rev Oncol Hematol       Date:  2001 Jul-Aug       Impact factor: 6.312

6.  Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

Authors:  Gregory A Wiseman; Ellen Kornmehl; Bryan Leigh; William D Erwin; Donald A Podoloff; Stewart Spies; Richard B Sparks; Michael G Stabin; Thomas Witzig; Christine A White
Journal:  J Nucl Med       Date:  2003-03       Impact factor: 10.057

7.  The response of mouse haemopoietic colony formers to acute or continuous gamma irradiation.

Authors:  N G Testa; J H Hendry; L G Lajtha
Journal:  Biomedicine       Date:  1973-05-20

8.  A purpose-built iodine-125 irradiation plaque for low dose rate low energy irradiation of cell lines in vitro.

Authors:  E G Aird; M Folkard; C R Mayes; P J Bownes; J M Lawson; M C Joiner
Journal:  Br J Radiol       Date:  2001-01       Impact factor: 3.039

9.  Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

Authors:  Thomas E Witzig; Ian W Flinn; Leo I Gordon; Christos Emmanouilides; Myron S Czuczman; Mansoor N Saleh; Larry Cripe; Gregory Wiseman; Teresa Olejnik; Pratik S Multani; Christine A White
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

10.  The radiation dosimetry of 2 [F-18]fluoro-2-deoxy-D-glucose in man.

Authors:  S C Jones; A Alavi; D Christman; I Montanez; A P Wolf; M Reivich
Journal:  J Nucl Med       Date:  1982-07       Impact factor: 10.057

View more
  3 in total

1.  Mice and the A-Bomb: Irradiation Systems for Realistic Exposure Scenarios.

Authors:  Guy Garty; Yanping Xu; Carl Elliston; Stephen A Marino; Gerhard Randers-Pehrson; David J Brenner
Journal:  Radiat Res       Date:  2017-02-17       Impact factor: 2.841

2.  Cellular Response to Exponentially Increasing and Decreasing Dose Rates: Implications for Treatment Planning in Targeted Radionuclide Therapy.

Authors:  Jay H Solanki; Thomas Tritt; Jordan B Pasternack; Julia J Kim; Calvin N Leung; Jason D Domogauer; Nicholas W Colangelo; Venkat R Narra; Roger W Howell
Journal:  Radiat Res       Date:  2017-05-25       Impact factor: 2.841

3.  VADER: a variable dose-rate external 137Cs irradiator for internal emitter and low dose rate studies.

Authors:  Guy Garty; Yanping Xu; Gary W Johnson; Lubomir B Smilenov; Simon K Joseph; Monica Pujol-Canadell; Helen C Turner; Shanaz A Ghandhi; Qi Wang; Rompin Shih; Robert C Morton; David E Cuniberti; Shad R Morton; Carlos Bueno-Beti; Thomas L Morgan; Peter F Caracappa; Evagelia C Laiakis; Albert J Fornace; Sally A Amundson; David J Brenner
Journal:  Sci Rep       Date:  2020-11-16       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.